Recombinant Vectors as Influenza Vaccines

The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopecky-Bromberg, Sarah A., Palese, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115000/
https://www.ncbi.nlm.nih.gov/pubmed/19768410
http://dx.doi.org/10.1007/978-3-540-92165-3_13
_version_ 1783514005380268032
author Kopecky-Bromberg, Sarah A.
Palese, Peter
author_facet Kopecky-Bromberg, Sarah A.
Palese, Peter
author_sort Kopecky-Bromberg, Sarah A.
collection PubMed
description The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors.
format Online
Article
Text
id pubmed-7115000
institution National Center for Biotechnology Information
language English
publishDate 2009
record_format MEDLINE/PubMed
spelling pubmed-71150002020-04-02 Recombinant Vectors as Influenza Vaccines Kopecky-Bromberg, Sarah A. Palese, Peter Vaccines for Pandemic Influenza Article The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors. 2009-06-15 /pmc/articles/PMC7115000/ /pubmed/19768410 http://dx.doi.org/10.1007/978-3-540-92165-3_13 Text en © Springer-Verlag Berlin Heidelberg 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Kopecky-Bromberg, Sarah A.
Palese, Peter
Recombinant Vectors as Influenza Vaccines
title Recombinant Vectors as Influenza Vaccines
title_full Recombinant Vectors as Influenza Vaccines
title_fullStr Recombinant Vectors as Influenza Vaccines
title_full_unstemmed Recombinant Vectors as Influenza Vaccines
title_short Recombinant Vectors as Influenza Vaccines
title_sort recombinant vectors as influenza vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115000/
https://www.ncbi.nlm.nih.gov/pubmed/19768410
http://dx.doi.org/10.1007/978-3-540-92165-3_13
work_keys_str_mv AT kopeckybrombergsaraha recombinantvectorsasinfluenzavaccines
AT palesepeter recombinantvectorsasinfluenzavaccines

Ejemplares similares